News NICE approval for Keytruda a 'milestone' in lung cancer But drug will not be funded for longer than two years.
News BMS' Opdivo approved in head and neck cancer BMS hopes survival data will give advantage over rival.
News BMS and Infinity look to boost Opdivo in lung cancer Companies look for combinations in lung cancer and other tumours.
News Scotland to fund BMS skin cancer combo Patient evidence convinces SMC Opdivo+Yervoy is cost-effective.
R&D Harnessing the cell's own degradation machinery, with Benedi... Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
